|
Home |
About Us |
Leadership |
News |
Contact Us |
Leadership |
|
|
|
|
|
|
Executive Team |
Peyton Anderson, MBA
Peyton is a successful entrepreneur who co-founded SciQuest, Inc. in 1995 as its founding CEO. SciQuest raised over $175 million in capital, including a successful Initial Public Offering in 1999. His responsibilities included raising capital, recruiting the management team, doing strategic partner deals, and orchestrating 8 acquisitions. SciQuest has continued to thrive and currently has greater than 150 employees.
|
|
Jonathan Gindes, MBA, RAC Jonathan and Affinergy's scientific co-founders (M. Grinstaff, D. Kenan) began working together in 2002 to form Affinergy while Jonathan pursued his M.B.A. at Duke's Fuqua School of Business. Jonathan developed Affinergy's initial business strategy, negotiated the technology license from Duke University, and recruited a senior management team along with other scientific staff and business advisors.
|
Bruce Lamb, Ph.D.
Bruce brings to Affinergy over 23 years of leadership experience in developing medical devices in the biosurgical area. He was most recently SVP of R&D and Regulatory Affairs at Lifecell which was acquired for $1.8 billion in 2008. Previously, Bruce was VP of Worldwide R&D for Biosurgicals at J&J's Ethicon division. Bruce also previously held leadership roles in product development at Convatec as well as Pfizer's Hospital Products Group.
|
|
Laura Kiefer, Ph.D., J.D.
Laura combines her scientific and legal training to strategically manage and build Affinergy's patent portfolio. She received a Ph.D. in Biochemistry from Duke University and a law degree at the University of North Carolina, Chapel Hill. Laura has over 10 years combined experience as a research scientist and patent agent/attorney in the biotechnology and pharmaceutical industries.
|
Daniel Kenan, M.D., Ph.D.
Dan is an Assistant Professor of Pathology at Duke University Medical Center. Dan received his Ph.D. in Microbiology and Immunology at Duke. He later received his M.D. at Duke where he continued residency training in Pathology.
|
|
Mark Grinstaff, Ph.D.
Mark is an Associate Professor of Chemistry and Biomedical Engineering at Boston University. This professorship is funded by a $14MM Whitaker Foundation Leadership Award. Mark received his Ph.D. from U. of Illinois and was an NIH Postdoctoral Fellow at the California Institute of Technology.
|
Board of Directors |
|
The Affinergy Board includes Peyton Anderson (CEO), Jonathan Gindes (CFO and Senior VP of Business Development) and four external Directors: |
|
Jeffery C. Basham, MBA |
Mr. Basham holds an undergraduate degree from The American University, Washington, DC and an MBA from Keller Graduate School (Chicago, IL). He has 30 years of experience in the healthcare product sector, including sales and marketing positions with Searle Pharmaceuticals and Ketchum Medical Advertising.
|
|
Bruce J. Boehm, MBA |
Mr. Boehm is an independent venture capitalist, an advisor to several specialty venture capital funds, and an adjunct lecturer at the Kenan Flagler School of Business at UNC, Chapel Hill. From 1992 to 1996 he created and directed the Masters of Engineering Management Program at the University of Canterbury in Christchurch, New Zealand.
|
|
Daniel A. Pelak |
Mr. Pelak is currently working with Welsh, Carson, Anderson & Stowe, a leading private equity group. He was previously the CEO of InnerPulse, Inc., a privately held medical device company that is pioneering a disruptive technology for the treatment of patients with heart disease. Prior to InnerPulse, he was CEO of Closure Medical, which was acquired by Johnson & Johnson for approximately $400 million.
|
|
David P. Rizzo |
David P. Rizzo is President and Chief Executive Officer of NC IDEA. A 13-year IBM veteran and successful entrepreneur, David joined NC IDEA (formerly known as MCNC Ventures) in June 2002. He brings more than 20 years of leadership experience in general management, strategic planning, acquisitions and divestitures, and corporate finance and investment in technologically-sophisticated business environments to NC IDEA.
|
Key Advisors |
|
Tom Amick, has 30 years experience with J&J where he spent most of his career in Ortho Biotech as a senior executive. Most recently he served as VP of Business development for Johnson & Johnson's Development Corporation (JJDC). Tom is an active Board member of emerging life science companies such as Biolex, Stemco (Chairman) among others. |
|
Jack Blair, M.B.A., was President of Smith & Nephew Richards Inc. and member of the Board of Smith & Nephew from 1989 to 1998, time at which he retired from the company. Jack presently serves as non-executive Chairman of dj Orthopedics, Inc., and as a director of NuVasive, Inc and Buckman Laboratories. |
|
Spencer Brown, Ph.D., is Director of Research of the Plastic Surgery Deptartment at UTSW. Prior to this, he served on NHLBI Study Sections. Dr. Brown established new clinical and basic research programs in LDL metabolism at Duke University. Dr. Brown received his PhD from the University of Pennsylvania and completed a postdoctoral fellowship at the at the Baylor College of Medicine. |
|
Hadley Callaway, M.D., holds a medical doctor degree from Harvard Medical School. His area of expertise is orthopedic surgery, an area where he performs both as a surgeon and a researcher. Dr. Callaway serves as an advisor to Affinergy for matters related to orthopedic devices and practices. |
|
William Costerton, Ph.D., is the Director of the Center for Biofilm Engineering at Montana State University. His expertise lies is in immunology and microbiology, with a particular focus on the biology of bacterial biofilms and their development on the surface of biomedical devices. |
|
Chris Fair, has over 15 years of orthopedic device management and development experience. Prior to joining MedShape Solutions, Inc., Chris served as the VP of Sales & Marketing for St. Francis Medical Technologies. Chris played an key role in the development of the company, the launch of the XSTOP and ultimately the sale of the company to Kyphon Inc. for $725MM. Prior to St. Francis, Chris held management positions with DePuy Spine for 10 years. |
|
Farshid Guilak, Ph.D., is an Associate Professor of Surgery and Director of Research for the Division of Orthopaedic Surgery at Duke University Medical Center. He serves as co-Director of Duke's Center for Biomolecular and Tissue Engineering. |
|
Peter C. Johnson, M.D., is a reconstructive microsurgeon who co-founded and served as CEO of TissueInformatics, then became CBO and Chief Medical Officer of Icoria (formerly Paradigm Genetics). He subsequently founded and is now President and CEO of Scintellix, LLC. He serves on the Board of Trustees of Carnegie Mellon University, the Pittsburgh Tissue Engineering Initiative and the Tissue Engineering Society, International. |
|
Rick Randall, joined TranS1 as full time CEO in June 2002. Previously, Mr. Randall founded and served as President and CEO of Incumed, Inc., a medical device incubator. He also served as President and CEO of the sports medicine firm, Innovasive Devices, Inc., and was President, Chairman and Director of Target Therapeutics, Inc., a medical device company that pioneered the minimally invasive, interventional neurosurgery market. |